The plot seems to thicken on the way to the Parkinson's cure!
 

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson's protein alpha-synuclein. Today the company announced its "boost" follow-up study -- funded with a $1.04 million grant from The Michael J. Fox Foundation -- showed that an additional dose is safe and can elicit antibodies against alpha-synuclein. AFFiRiS will present a poster on the study at the World Parkinson Congress in Portland, Oregon on Wednesday, September 21.

Parkinson's Disease | Vaccine for Parkinson's Reports Positive Results from Boost Study

Review of immunotherapy for PD
 

The whole area of immunotherapy for PD is new for me, so I did some reading to try to get a basic understanding. In the process I came across quite a good review article, which is also fairly recent (2015). It covers both active immunotherapy (injecting "manufactured" antigens) and passive immunotherapy (injecting "manufactured" antibodies). The active immunotherapy section includes a paragraph describing the work of AFFiRiS.

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation - IOS Press